$91.4 Million is the total value of Asymmetry Capital Management, L.P.'s 29 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $10,494,000 | +441.2% | 249,866 | +485.3% | 11.48% | +230.3% |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB-CVRrts | $9,061,000 | +623.7% | 2,384,487 | +473.3% | 9.91% | +341.6% |
| BAX | Buy | BAXTER INTERNATIONAL INC | $6,149,000 | +40.9% | 75,737 | +45.1% | 6.72% | -14.0% |
| GH | Buy | GUARDANT HEALTH INC | $5,320,000 | +93.2% | 76,438 | +116.9% | 5.82% | +17.9% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $4,620,000 | +61.8% | 54,676 | +61.9% | 5.05% | -1.3% |
| PTCT | Buy | PTC THERAPEUTICS | $4,482,000 | +68.4% | 100,470 | +81.3% | 4.90% | +2.8% |
| BIO | Buy | BIO-RAD LABORATORIES-A | $4,444,000 | +89.1% | 12,676 | +99.6% | 4.86% | +15.4% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $4,423,000 | – | 86,577 | +100.0% | 4.84% | – |
| UNH | Buy | UNITEDHEALTH GROUP INC | $3,943,000 | +109.1% | 15,811 | +146.5% | 4.31% | +27.6% |
| TWST | Buy | TWIST BIOSCIENCE CORP | $3,796,000 | +232.7% | 124,120 | +128.4% | 4.15% | +103.0% |
| MYOK | Buy | MYOKARDIA INC | $3,409,000 | +103.2% | 72,712 | +215.8% | 3.73% | +23.9% |
| ASND | Buy | ASCENDIS PHARMA A/S - ADRadr | $3,171,000 | +248.1% | 28,157 | +330.1% | 3.47% | +112.4% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $2,940,000 | +205.6% | 318,152 | +222.3% | 3.22% | +86.5% |
| FATE | New | FATE THERAPEUTICS INC | $2,667,000 | – | 120,103 | +100.0% | 2.92% | – |
| CYTK | Buy | CYTOKINETICS INC | $2,408,000 | +166.4% | 204,251 | +139.8% | 2.63% | +62.6% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $2,260,000 | +83.0% | 83,087 | +32.8% | 2.47% | +11.7% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $2,078,000 | -20.0% | 32,292 | -25.9% | 2.27% | -51.2% |
| VAR | Buy | VARIAN MEDICAL SYSTEMS INC | $1,795,000 | +112.9% | 17,484 | +194.6% | 1.96% | +29.9% |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $1,792,000 | – | 74,501 | +100.0% | 1.96% | – |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $1,736,000 | +126.6% | 855,318 | +141.0% | 1.90% | +38.3% |
| QURE | New | UNIQURE NV | $1,534,000 | – | 32,331 | +100.0% | 1.68% | – |
| TXG | New | 10X GENOMICS INC-CLASS A | $1,533,000 | – | 24,603 | +100.0% | 1.68% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $1,469,000 | – | 15,016 | +100.0% | 1.61% | – |
| AVRO | New | AVROBIO INC | $1,331,000 | – | 85,554 | +100.0% | 1.46% | – |
| IMMU | New | IMMUNOMEDICS INC | $1,242,000 | – | 92,147 | +100.0% | 1.36% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,128,000 | – | 762,219 | +100.0% | 1.23% | – |
| NCNA | Buy | NUCANA PLC-ADRadr | $1,085,000 | +11.3% | 186,187 | +16.4% | 1.19% | -32.1% |
| CNC | Sell | CENTENE CORP | $969,000 | -65.3% | 16,318 | -63.3% | 1.06% | -78.8% |
| XCUR | Sell | EXICURE INC | $157,000 | -89.0% | 106,096 | -78.8% | 0.17% | -93.3% |
| APLS | Exit | APELLIS PHARMACEUTICALS | $0 | – | -21,380 | -100.0% | -1.17% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -6,950 | -100.0% | -1.61% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -256,205 | -100.0% | -1.94% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -49,431 | -100.0% | -2.12% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -15,004 | -100.0% | -2.20% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -20,791 | -100.0% | -2.42% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC | $0 | – | -22,872 | -100.0% | -2.44% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -81,127 | -100.0% | -2.58% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -62,507 | -100.0% | -2.71% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -18,921 | -100.0% | -3.00% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -4,584 | -100.0% | -3.08% | – |
| MYL | Exit | MYLAN NV | $0 | – | -132,855 | -100.0% | -4.79% | – |
| INSM | Exit | INSMED INC | $0 | – | -113,875 | -100.0% | -4.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.